Johan Richter

Search results

• 2022

  Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register study

  Dahlén, T., Edgren, G., Ljungman, P., Flygt, H., Richter, J., Olsson-Strömberg, U., Wadenvik, H., Dreimane, A., Myhr-Eriksson, K., Zhao, J., Själander, A., Höglund, M. & Stenke, L., 2022, In: American Journal of Hematology. 97, 4, p. 421-430 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 100%
  • Protein-Tyrosine Kinases 86%
  • insulin receptor-related receptor 35%
  • Morbidity 21%
  • Myocardial Infarction 17%
• 2021

  Gene therapy for infantile malignant osteopetrosis: review of pre-clinical research and proof-of-concept for phenotypic reversal

  Moscatelli, I., Almarza, E., Schambach, A., Ricks, D., Schulz, A., Herzog, C. D., Henriksen, K., Askmyr, M., Schwartz, J. D. & Richter, J., 2021, In: Molecular Therapy - Methods and Clinical Development. 20, p. 389-397 9 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Osteopetrosis 100%
  • Proof of Concept Study 87%
  • Hematopoietic Stem Cells 68%
  • Genetic Therapy 64%
  • Graft vs Host Disease 12%

• Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study

  Flygt, H., Söderlund, S., Stentoft, J., Richter, J., Koskenvesa, P., Mustjoki, S., Majeed, W., Lübking, A., Dreimane, A., Markevärn, B., Stenke, L., Myhr Eriksson, K., Gjertsen, B. T., Gedde-Dahl, T., Dimitrijevic, A., Udby, L., Olsson-Strömberg, U. & Hjorth-Hansen, H., 2021, In: European Journal of Haematology. 107, 6, p. 617-623

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Dasatinib 100%
  • Leukemia, Myeloid, Chronic Phase 99%
  • Protein-Tyrosine Kinases 32%
  • galantide 25%
  • Interferons 16%

• Successful tyrosine kinase inhibitor discontinuation outside clinical trials — data from the population-based Swedish chronic myeloid leukaemia registry

  Flygt, H., Sandin, F., Dahlén, T., Dremaine, A., Lübking, A., Markevärn, B., Myhr-Eriksson, K., Olsson, K., Olsson-Strömberg, U., Själander, A., Söderlund, S., Wennström, L., Wadenvik, H., Stenke, L., Höglund, M. & Richter, J., 2021, In: British Journal of Haematology. 193, 5, p. 915-921

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 100%
  • Protein-Tyrosine Kinases 86%
  • Registries 75%
  • Clinical Trials 61%
  • Population 37%
• 2020

  A high-content cytokine screen identifies myostatin propeptide as a positive regulator of primitive chronic myeloid leukemia cells

  von Palffy, S., Landberg, N., Sandén, C., Zacharaki, D., Shah, M., Nakamichi, N., Hansen, N., Askmyr, M., Lilljebjörn, H., Rissler, M., Karlsson, C., Scheding, S., Richter, J., Eaves, C. J., Bhatia, R., Järås, M. & Fioretos, T., 2020, In: Haematologica. 105, 8, p. 2095-2104 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Myostatin 100%
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 74%
  • Myeloid Cells 71%
  • Cytokines 43%
  • Bone Marrow Cells 9%

• European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

  Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., Hjorth-Hansen, H., Hughes, T. P., Janssen, J. J. W. M., Kantarjian, H. M., Kim, D. W., Larson, R. A., Lipton, J. H., Mahon, F. X., Mayer, J., Nicolini, F., & 14 othersNiederwieser, D., Pane, F., Radich, J. P., Rea, D., Richter, J., Rosti, G., Rousselot, P., Saglio, G., Saußele, S., Soverini, S., Steegmann, J. L., Turkina, A., Zaritskey, A. & Hehlmann, R., 2020 Apr, In: Leukemia. 34, 4, p. 966-984 19 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 100%
  • Imatinib Mesylate 24%
  • bosutinib 17%
  • Therapeutics 15%
  • 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide 15%

• Generation of gene-corrected functional osteoclasts from osteopetrotic induced pluripotent stem cells

  Xian, X., Moraghebi, R., Löfvall, H., Fasth, A., Henriksen, K., Richter, J., Woods, N. B. & Moscatelli, I., 2020 May 15, In: Stem Cell Research & Therapy. 11, 179.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Induced Pluripotent Stem Cells 100%
  • Osteoclasts 91%
  • Mutation 74%
  • Osteopetrosis 54%
  • Biological Marker 39%

• Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy

  Söderlund, S., Persson, I., Ilander, M., Guilhot, J., Hjorth-Hansen, H., Koskenvesa, P., Richter, J., Saussele, S., Mustjoki, S. & Olsson-Strömberg, U., 2020, In: Leukemia Research. 90, 106310.

  Research output: Contribution to journal › Article › peer-review

  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 100%
  • Proteomics 87%
  • Protein-Tyrosine Kinases 86%
  • Biomarkers 61%
  • Blood Proteins 60%
• 2019

  Hematopoietic stem cell-targeted neonatal gene therapy with a clinically applicable lentiviral vector corrects osteopetrosis in oc/oc Mice

  Löfvall, H., Rothe, M., Schambach, A., Henriksen, K., Richter, J. & Moscatelli, I., 2019, In: Human Gene Therapy. 30, 11, p. 1395-1404 10 p.

  Research output: Contribution to journal › Article › peer-review

  • Osteopetrosis 100%
  • Hematopoietic Stem Cells 68%
  • Genetic Therapy 64%
  • Osteoclasts 61%
  • Peptide Elongation Factor 1 29%

• Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

  Kreutzman, A., Yadav, B., Brummendorf, T. H., Gjertsen, B. T., Lee Hee, M., Janssen, J., Kasanen, T., Koskenvesa, P., Lofti, K., Markevärn, B., Olsson-Strömberg, U., Stentoft, J., Stenke, L., Söderlund, S., Udby, L., Richter, J., Hjorth-Hansen, H. & Mustjoki, S., 2019 Jul 13, In: OncoImmunology. 8, 9, e1638210.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • bosutinib 100%
  • Immunologic Monitoring 77%
  • Imatinib Mesylate 67%
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 62%
  • Natural Killer Cells 46%
• 2018

  CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting

  Landberg, N., von Palffy, S., Askmyr, M., Lilljebjörn, H., Sandén, C., Rissler, M., Mustjoki, S., Hjorth-Hansen, H., Richter, J., Ågerstam, H., Järås, M. & Fioretos, T., 2018 Feb 28, In: Haematologica. 103, 3, p. 447-455

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Imatinib Mesylate 100%
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 92%
  • Myeloid Cells 89%
  • Antibodies 48%
  • Protein-Tyrosine Kinases 40%

• Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

  Saussele, S., Richter, J., Guilhot, J., Gruber, F. X., Hjorth-Hansen, H., Almeida, A., Janssen, J. J. W. M., Mayer, J., Koskenvesa, P., Panayiotidis, P., Olsson-Strömberg, U., Martinez-Lopez, J., Rousselot, P., Vestergaard, H., Ehrencrona, H., Kairisto, V., Machová Poláková, K., Müller, M. C., Mustjoki, S., Berger, M. G., & 6 othersFabarius, A., Hofmann, W. K., Hochhaus, A., Pfirrmann, M., Mahon, F. X. & EURO-SKI investigators, 2018 Jun, In: The Lancet Oncology. 19, 6, p. 747-757

  Research output: Contribution to journal › Article › peer-review

  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 100%
  • Protein-Tyrosine Kinases 86%
  • Therapeutics 15%
  • Survival 15%
  • Leukemia, Myeloid, Chronic Phase 15%

• Interleukin 4 induces apoptosis of acute myeloid leukemia cells in a Stat6 dependent manner

  Peña, P., Eriksson, M., Ramakrishnan, R., Chapellier, M., Högberg, C., Orsmark-Pietras, C., Richter, J., Andersson, A., Fioretos, T. & Järås, M., 2018, In: Leukemia. 32, 3, p. 588-596

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Myeloid Cells 100%
  • Acute Myeloid Leukemia 93%
  • Interleukin-4 90%
  • Apoptosis 59%
  • Leukemia 13%

• Osteoclasts degrade bone and cartilage knee joint compartments through different resorption processes

  Löfvall, H., Newbould, H., Karsdal, M. A., Dziegiel, M. H., Richter, J., Henriksen, K. & Thudium, C. S., 2018 Apr 10, In: Arthritis Research and Therapy. 20, 1, 67.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Osteoclasts 100%
  • Knee Joint 98%
  • Cartilage 84%
  • E 64 78%
  • N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide 77%

• Prospective evaluation of a combination of fungal biomarkers for the diagnosis of invasive fungal disease in high-risk haematology patients

  Hammarström, H., Stjärne Aspelund, A., Christensson, B., Heußel, C. P., Isaksson, J., Kondori, N., Larsson, L., Markowicz, P., Richter, J., Wennerås, C. & Friman, V., 2018 Sep 1, In: Mycoses. 61, 9, p. 623-632 10 p.

  Research output: Contribution to journal › Article › peer-review

  • Hematology 100%
  • Mycoses 94%
  • galactomannan 82%
  • Gliotoxin 61%
  • Biomarkers 60%

• Targeting NSG Mice Engrafting Cells with a Clinically Applicable Lentiviral Vector Corrects Osteoclasts in Infantile Malignant Osteopetrosis

  Moscatelli, I., Löfvall, H., Schneider Thudium, C., Rothe, M., Montano, C., Kertész, Z., Sirin, M., Schulz, A., Schambach, A., Henriksen, K. & Richter, J., 2018, In: Human Gene Therapy. 29, 8, p. 938-949

  Research output: Contribution to journal › Article › peer-review

  • Osteopetrosis 100%
  • Osteoclasts 71%
  • Peptide Elongation Factor 1 69%
  • Proton Pumps 10%
  • Bone and Bones 9%
• 2017

  Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register

  Söderlund, S., Dahlén, T., Sandin, F., Olsson-Strömberg, U., Creignou, M., Dreimane, A., Lübking, A., Markevärn, B., Själander, A., Wadenvik, H., Stenke, L., Richter, J. & Höglund, M., 2017 Jan, In: European Journal of Haematology. 98, 1, p. 57-66

  Research output: Contribution to journal › Article › peer-review

  • Leukemia, Myeloid, Chronic Phase 100%
  • Blast Crisis 99%
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 76%
  • Protein-Tyrosine Kinases 66%
  • Disease Progression 29%

• Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NFκB-dependent differentiation of AML cells

  Eriksson, M., Peña-Martínez, P., Ramakrishnan, R., Chapellier, M., Högberg, C., Glowacki, G., Orsmark-Pietras, C., Velasco-Hernández, T., Lazarević, V. L., Juliusson, G., Cammenga, J., Mulloy, J. C., Richter, J., Fioretos, T., Ebert, B. L. & Järås, M., 2017 Oct 24, In: Blood Advances. 1, 23, p. 2046-2057 12 p.

  Research output: Contribution to journal › Article › peer-review

  • Toll-Like Receptor 1 100%
  • p38 Mitogen-Activated Protein Kinases 65%
  • Myeloid Cells 65%
  • Acute Myeloid Leukemia 60%
  • Apoptosis 38%

• Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Hochhaus, A., Saussele, S., Rosti, G., Mahon, F-X., Janssen, J. J. W. M., Hjorth-Hansen, H., Richter, J., Buske, C. & ESMO Guidelines Committee, 2017, In: Annals of Oncology. 28, p. iv41-iv51

  Research output: Contribution to journal › Article › peer-review

• Forced expression of human macrophage colony-stimulating factor in CD34⁺ cells promotes monocyte differentiation in vitro and in vivo but blunts osteoclastogenesis in vitro

  Montano, C., Thudium, C. S., Löfvall, H., Moscatelli, I., Schambach, A., Henriksen, K. & Richter, J., 2017 Feb 3, In: European Journal of Haematology.

  Research output: Contribution to journal › Article › peer-review

  • Macrophage Colony-Stimulating Factor 100%
  • Osteogenesis 72%
  • Monocytes 68%
  • Fetal Blood 36%
  • In Vitro Techniques 36%

• Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia

  Ilander, M., Olsson-Strömberg, U., Schlums, H., Guilhot, J., Brück, O., Lähteenmäki, H., Kasanen, T., Koskenvesa, P., Söderlund, S., Höglund, M., Markevärn, B., Själander, A., Lotfi, K., Dreimane, A., Lübking, A., Holm, E., Björeman, M., Lehmann, S., Stenke, L., Ohm, L., & 11 othersGedde-Dahl, T., Majeed, W., Ehrencrona, H., Koskela, S., Saussele, S., Mahon, F. X., Porkka, K., Hjorth-Hansen, H., Bryceson, Y. T., Richter, J. & Mustjoki, S., 2017 May 1, In: Leukemia. 31, 5, p. 1108-1116 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Imatinib Mesylate 100%
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 92%
  • Natural Killer Cells 81%
  • T-Lymphocytes 20%
  • Protein-Tyrosine Kinases 20%

• Kronisk myeloisk leukemi: förebild för målstyrd terapi - Revolutionerande överlevnadsvinster med definitiv bot i sikte och kraftigt förbättrad hälsoekonomi

  Richter, J. & Stenke, L., 2017 Sep 21, In: Läkartidningen. 114, 3 p.

  Research output: Contribution to journal › Article

• Kronisk myeloisk leukemi: Förebild för målstyrd terapi

  Translated title of the contribution: Chronic myeloid leukemia - A model disease for targeted therapyRichter, J. & Stenke, L., 2017, In: Läkartidningen. 114, 39, p. 1574 1 p.

  Research output: Contribution to journal › Debate/Note/Editorial

  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 100%
  • Protein-Tyrosine Kinases 86%
  • Imatinib Mesylate 81%
  • bcr-abl Fusion Proteins 38%
  • Philadelphia Chromosome 30%

• Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe

  Belmatoug, N., Di Rocco, M., Fraga, C., Giraldo, P., Hughes, D., Lukina, E., Maison-Blanche, P., Merkel, M., Niederau, C., Plöckinger, U., Richter, J., Stulnig, T. M., vom Dahl, S. & Cox, T. M., 2017, In: European Journal of Internal Medicine. 37, p. 25-32

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • eliglustat 100%
  • Gaucher Disease 67%
  • Cytochrome P-450 CYP2D6 19%
  • Glucosylceramides 14%
  • Enzyme Therapy 14%

• No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia: A population-based study in Sweden

  Gunnarsson, N., Höglund, M., Stenke, L., Sandin, F., Björkholm, M., Dreimane, A., Lambe, M., Markevärn, B., Olsson-Strömberg, U., Wadenvik, H., Richter, J. & Själander, A., 2017 Aug 1, In: Leukemia. 31, 8, p. 1825-1827 3 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML

  Warfvinge, R., Geironson Ulfsson, L., Sommarin, M. N. E., Lang, S., Karlsson, C., Roschupkina, T., Stenke, L., Stentoft, J., Olsson-Strömberg, U., Hjorth-Hansen, H., Mustjoki, S., Soneji, S., Richter, J. & Karlsson, G., 2017 Apr, In: Blood. 129, 17, p. 2384-2394

  Research output: Contribution to journal › Article › peer-review

  • Single-Cell Analysis 100%
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 78%
  • Heterogeneity 68%
  • Tyrosine 67%
  • Stem Cells 54%

• The impact of socio-economic factors on treatment choice and mortality in chronic myeloid leukaemia

  Larfors, G., Sandin, F., Richter, J., Själander, A., Stenke, L., Lambe, M. & Höglund, M., 2017, In: European Journal of Haematology. 98, 4, p. 398-406 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 100%
  • Economics 73%
  • Mortality 47%
  • Survival 35%
  • Income 26%

• Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia

  Rajala, H. L. M., El Missiry, M., Ruusila, A., Koskenvesa, P., Brümmendorf, T. H., Gjertsen, B. T., Janssen, J. J., Lotfi, K., Markevärn, B., Olsson-Strömberg, U., Stenke, L., Stentoft, J., Richter, J., Hjorth-Hansen, H., Kreutzman, A. & Mustjoki, S., 2017, In: Journal of Cancer Research and Clinical Oncology. 143, 8, p. 1543-1554

  Research output: Contribution to journal › Article › peer-review

  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 100%
  • Humoral Immunity 98%
  • Protein-Tyrosine Kinases 86%
  • Imatinib Mesylate 54%
  • Dasatinib 32%
• 2016

  Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia

  Dahlén, T., Edgren, G., Lambe, M., Höglund, M., Björkholm, M., Sandin, F., Själander, A., Richter, J., Olsson-Strömberg, U., Ohm, L., Bäck, M. & Stenke, L., 2016 Aug 2, In: Annals of Internal Medicine. 165, 3, p. 161-166 6 p.

  Research output: Contribution to journal › Article › peer-review

  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 100%
  • Protein-Tyrosine Kinases 86%
  • Myocardial Infarction 18%
  • Sweden 16%
  • 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide 12%

• IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models

  Ågerstam, H., Hansen, N., von Palffy, S., Sandén, C., Reckzeh, K., Karlsson, C., Lilljebjörn, H., Landberg, N., Askmyr, M., Högberg, C., Rissler, M., Porkka, K., Wadenvik, H., Mustjoki, S., Richter, J., Järås, M. & Fioretos, T., 2016 Dec 8, In: Blood. 128, 23, p. 2683-2693

  Research output: Contribution to journal › Article › peer-review

  • Tyrosine Kinase Inhibitor 100%
  • Myeloid Progenitor Cells 96%
  • Effector 78%
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 75%
  • Interleukin-1 71%

• Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia

  Gunnarsson, N., Höglund, M., Stenke, L., Wallberg-Jonsson, S., Sandin, F., Björkholm, M., Dreimane, A., Lambe, M., Markevärn, B., Olsson-Strömberg, U., Wadenvik, H., Richter, J. & Själander, A., 2016 Jul 1, In: Leukemia. 30, 7, p. 1562-1567 6 p.

  Research output: Contribution to journal › Article › peer-review

  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 100%
  • Autoimmune Diseases 82%
  • Neoplasms 30%
  • Chronic Disease 19%
  • Protein-Tyrosine Kinases 15%

• In vivo CYP3A activity and pharmacokinetics of imatinib in relation to therapeutic outcome in chronic myeloid leukemia patients.

  Skoglund, K., Richter, J., Olsson-Strömberg, U., Bergquist, J., Aluthgedara, W., Ubhayasekera, S. J. K. A., Vikingsson, S., Svedberg, A., Söderlund, S., Sandstedt, A., Johnsson, A., Aagesen, J., Alsenhed, J., Hägg, S., Peterson, C., Lotfi, K. & Gréen, H., 2016, In: Therapeutic Drug Monitoring. 38, 2, p. 230-238

  Research output: Contribution to journal › Article › peer-review

  • Imatinib Mesylate 100%
  • Cytochrome P-450 CYP3A 99%
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 92%
  • Pharmacokinetics 66%
  • Protein-Tyrosine Kinases 40%

• Leukemic stem cell quantification in newly diagnosed chronic myeloid leukemia patients predicts response to nilotinib therapy

  Thielen, N., Richter, J., Baldauf, M., Barbany, G., Fioretos, T., Giles, F., Gjertsen, B. T., Hochhaus, A., Schuurhuis, G. J., Sopper, S., Stenke, L., Thunberg, S., Wolf, D., Ossenkoppele, G., Porkka, K., Janssen, J. & Mustjoki, S., 2016 Aug 15, In: Clinical Cancer Research. 22, 16, p. 4030-4038 9 p.

  Research output: Contribution to journal › Article › peer-review

  • 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide 100%
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 72%
  • Stem Cells 50%
  • Bone Marrow Cells 14%
  • Therapeutics 11%

• Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli

  Söderlund, S., Christiansson, L., Persson, I., Hjorth-Hansen, H., Richter, J., Simonsson, B., Mustjoki, S., Olsson-Strömberg, U. & Loskog, A., 2016 Nov 1, In: Leukemia Research. 50, p. 95-103 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 100%
  • Proteomics 87%
  • Protein-Tyrosine Kinases 86%
  • Immunity 77%
  • Blood Proteins 42%

• Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence.

  Gunnarsson, N., Sandin, F., Höglund, M., Stenke, L., Björkholm, M., Lambe, M., Olsson-Strömberg, U., Richter, J. & Själander, A., 2016, In: European Journal of Haematology. 97, 4, p. 387-392

  Research output: Contribution to journal › Article › peer-review

  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 100%
  • Sweden 93%
  • Survival 52%
  • Population 37%
  • Medical Economics 16%

• Quantitative Analysis of Mutant Subclones in Chronic Myeloid Leukemia: Comparison of Different Methodological Approaches

  Preuner, S., Barna, A., Frommlet, F., Czurda, S., Konstantin, B., Alikian, M., Machova Polakova, K., Sacha, T., Richter, J., Lion, T. & Gabriel, C., 2016 Apr 29, In: International Journal of Molecular Sciences. 17, 5

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • leukemias 100%
  • sequencing 94%
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 72%
  • quantitative analysis 69%
  • High-Throughput Nucleotide Sequencing 66%

• Regulation and Function of Lentiviral Vector-Mediated TCIRG1 Expression in Osteoclasts from Patients with Infantile Malignant Osteopetrosis: Implications for Gene Therapy

  Thudium, C. S., Moscatelli, I., Löfvall, H., Kertész, Z., Montano, C., Bjurström, C. F., Karsdal, M. A., Schulz, A., Richter, J. & Henriksen, K., 2016, In: Calcified Tissue International. 99, 6, p. 638-648 11 p.

  Research output: Contribution to journal › Article › peer-review

  • Osteopetrosis 100%
  • Osteoclasts 71%
  • Genetic Therapy 64%
  • Bone and Bones 13%
  • Proteins 12%

• The concept of treatment-free remission in chronic myeloid leukemia

  Saußele, S., Richter, J., Hochhaus, A. & Mahon, F. X., 2016 Aug 1, In: Leukemia. 30, 8, p. 1638-1647 10 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 100%
  • Protein-Tyrosine Kinases 51%
  • Therapeutics 15%
  • Registries 15%
  • Clinical Trials 12%
• 2015

  Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.

  Ågerstam, H., Karlsson, C., Hansen, N., Sandén, C., Askmyr, M., von Palffy, S., Högberg, C., Rissler, M., Wunderlich, M., Juliusson, G., Richter, J., Sjöström, K., Bhatia, R., Mulloy, J. C., Järås, M. & Fioretos, T., 2015, In: Proceedings of the National Academy of Sciences. 112, 34, p. 10786-10791

  Research output: Contribution to journal › Article › peer-review

  Open Access

  File

  • Acute Myeloid Leukemia 100%
  • Heterografts 94%
  • Therapeutic Uses 86%
  • Antibodies 58%
  • Interleukin-1 44%
  297 Downloads (Pure)

• Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib.

  Palmason, R., Lindén, O. & Richter, J., 2015, In: BMC Hematology. 15, p. 10

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • INCB018424 100%
  • Lymphoproliferative Disorders 75%
  • Human Herpesvirus 4 63%
  • Janus Kinase 1 51%
  • Janus Kinase 2 45%

• Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)

  Hjorth-Hansen, H., Stenke, L., Soderlund, S., Dreimane, A., Ehrencrona, H., Gedde-Dahl, T., Gjertsen, B. T., Hoglund, M., Koskenvesa, P., Lotfi, K., Majeed, W., Markevarn, B., Ohm, L., Olsson-Stromberg, U., Remes, K., Suominen, M., Simonsson, B., Porkka, K., Mustjoki, S. & Richter, J., 2015, In: European Journal of Haematology. 94, 3, p. 243-250

  Research output: Contribution to journal › Article › peer-review

  Open Access

  File

  • Dasatinib 100%
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 76%
  • Imatinib Mesylate 58%
  • Intention to Treat Analysis 12%
  • Cytogenetics 10%
  39 Downloads (Pure)

• IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome.

  Landberg, N., Hansen, N., Askmyr, M., Ågerstam, H., Lassen, C., Rissler, M., Hansen, H. H., Mustjoki, S., Järås, M., Richter, J. & Fioretos, T., 2015, In: Leukemia. 30, 1, p. 255-258

  Research output: Contribution to journal › Article › peer-review

  File
  619 Downloads (Pure)

• Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era

  Gunnarsson, N., Stenke, L., Hoglund, M., Sandin, F., Bjorkholm, M., Dreimane, A., Lambe, M., Markevarn, B., Olsson-Stromberg, U., Richter, J., Wadenvik, H., Wallvik, J. & Sjalander, A., 2015, In: British Journal of Haematology. 169, 5, p. 683-688

  Research output: Contribution to journal › Article › peer-review

  • Second Primary Neoplasms 100%
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 92%
  • Protein-Tyrosine Kinases 79%
  • Nose Neoplasms 39%
  • Gastrointestinal Neoplasms 14%

• The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses

  Christiansson, L., Soderlund, S., Mangsbo, S., Hjorth-Hansen, H., Hoglund, M., Markevarn, B., Richter, J., Stenke, L., Mustjoki, S., Loskog, A. & Olsson-Stromberg, U., 2015, In: Molecular Cancer Therapeutics. 14, 5, p. 1181-1191

  Research output: Contribution to journal › Article › peer-review

  • Dasatinib 100%
  • Imatinib Mesylate 82%
  • Myeloid Cells 73%
  • Protein-Tyrosine Kinases 65%
  • Lymphocytes 50%
• 2014

  A Comparison of Osteoclast-Rich and Osteoclast-Poor Osteopetrosis in Adult Mice Sheds Light on the Role of the Osteoclast in Coupling Bone Resorption and Bone Formation

  Thudium, C., Moscatelli, I., Flores Bjurström, C., Thomsen, J. S., Bruel, A., Gudmann, N. S., Hauge, E-M., Karsdal, M. A., Richter, J. & Henriksen, K., 2014, In: Calcified Tissue International. 95, 1, p. 83-93

  Research output: Contribution to journal › Article › peer-review

  • Mild autosomal recessive form Osteopetrosis 100%
  • Osteoclasts 46%
  • Bone Resorption 45%
  • Osteogenesis 39%
  • Bone and Bones 26%

• Modeling chronic myeloid leukemia in immunodeficient mice reveals expansion of aberrant mast cells and accumulation of pre-B cells.

  Askmyr, M., Ågerstam, H., Lilljebjörn, H., Hansen, N., Karlsson, C., von Palffy, S., Landberg, N., Högberg, C., Lassen, C., Rissler, M., Richter, J., Ehinger, M., Järås, M. & Fioretos, T., 2014, In: Blood Cancer Journal. 4, e269.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  File

  • B-Lymphoid Precursor Cells 100%
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 87%
  • Mast Cells 80%
  • Leukemia, Myeloid, Chronic Phase 37%
  • Blast Crisis 37%
  405 Downloads (Pure)

• Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome?

  Richter, J., Söderlund, S., Lübking, A., Dreimane, A., Lotfi, K., Markevärn, B., Själander, A., Saussele, S., Olsson-Strömberg, U. & Stenke, L., 2014, In: Journal of Clinical Oncology. 32, 25, p. 2821-2823

  Research output: Contribution to journal › Letter

• RNA-seq identifies clinically relevant fusion genes in leukemia including a novel MEF2D/CSF1R fusion responsive to imatinib.

  Lilljebjörn, H., Ågerstam, H., Orsmark Pietras, C., Rissler, M., Ehrencrona, H., Nilsson, L., Richter, J. & Fioretos, T., 2014, In: Leukemia. 28, 4, p. 977-979

  Research output: Contribution to journal › Letter › peer-review

  File
  501 Downloads (Pure)
• 2013

  Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients

  Mustjoki, S., Richter, J., Barbany, G., Ehrencrona, H., Fioretos, T., Gedde-Dahl, T., Gjertsen, B. T., Hovland, R., Hernesniemi, S., Josefsen, D., Koskenvesa, P., Dybedal, I., Markevarn, B., Olofsson, T., Olsson-Stromberg, U., Rapakko, K., Thunberg, S., Stenke, L., Simonsson, B., Porkka, K., & 1 othersHjorth-Hansen, H., 2013, In: Leukemia. 27, 7, p. 1520-1526

  Research output: Contribution to journal › Article › peer-review

  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 100%
  • Stem Cells 69%
  • Dasatinib 65%
  • Protein-Tyrosine Kinases 64%
  • Imatinib Mesylate 54%

• Lentiviral gene transfer of TCIRG1 into peripheral blood CD34(+) cells restores osteoclast function in infantile malignant osteopetrosis.

  Moscatelli, I., Thudium, C., Flores Bjurström, C., Schulz, A., Askmyr, M., Gudmann, N. S., Andersen, N. M., Porras, O., Karsdal, M. A., Villa, A., Fasth, A., Henriksen, K. & Richter, J., 2013, In: Bone. 57, 1, p. 1-9

  Research output: Contribution to journal › Article › peer-review

  • Osteopetrosis 100%
  • Osteoclasts 71%
  • Blood Cells 57%
  • Genes 28%
  • Bone and Bones 23%